The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
No offence meant but maybe you should go back and read the RNS again. Characterisation study not due to complete until q4 2022, testing expected early 2023.
Anyone have any thoughts on how the latest appointee might approach challenge studies, vaccine trials etc.
For me Han**** was fairly gung ho, Javid a career fencesitter who was never going to sign off on anything contentious. The new guy I know nothing about.
Yet 10mins later multiple trades at 12.39p shown as buys. Hmm, must be the algos!!!
Exactly as predicted, you must be a clairvoyant
Note the absence of a £ sign in my post. 2m shares:-)
I hope its not Mo, I was thinking if he has faith in his own abilities, he would be good for at the very least a 2m share buy.
Thanks Ex, hard to disagree with the glacial pace of things. If my memory serves me correctly, wasn't there some problem with growing the delta strain in the lab, which in turn impacted the timescales for completing the characterisation study. If Hvivo now have a live delta version we could see some sort of challenge study by end of 2022.
Posted by M5 on the other board. Challenge studies using the delta variant?
https://twitter.com/Eskers1/status/1541018392227991553
So as it stands right now, I am £12k up on polb, £30k down on Orph. Baffling to say the least. I just hope the year end results aren't already baked in to the Sp and we get a 20% uplift post ER.
@IMozi, you are probably correct. Could just as easily be a group of shorters at work.
Beginning to think the constant seller may be him reducing his holding. Very few pi's left with decent profits at 13p
Ha ha, thanks for that Moni, I was thinking about composing a witty repost to our resident milk monitor, but you did it for me. Keyboard warriors don't you just love them.
Nice Tr1, schroders at 5%
Great post Nathan, nice to get an insight into the wider industry based view, on the space Orph operates within.
Like you I increased my holding as the business case improved and am sitting at a 19p average with a decent chunk of shares.
Would like to see us get to 45p without a sale. Biggest concern I have is, if the ex director who has 10m+ shares, offloads in June, the sp will take another massive downturn.
Beginning to think its the other way around. They know exactly what they have and are trying to frustrate Orph into capitulation, in advance of any sale of Orph.